Fml

Iron Deficiency Anemia, Iron deficiency, Breastfeeding + 8 more

Treatment

1 FDA approval

20 Active Studies for Fml

Treatment for

Iron Deficiency Anemia

What is Fml

Ferrous sulfate anhydrousThe Generic name of this drug

Treatment SummaryFerrous sulfate is a synthetic drug commonly used to treat iron deficiency anemia. It is considered the best oral iron therapy to address iron deficiencies in young children, infants, and women of childbearing age. Ferrous sulfate is widely used in the UK and many other countries to treat iron deficiency anemia.

Tri-Vitamin with iron and fluorideis the brand name

image of different drug pills on a surface

Fml Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Tri-Vitamin with iron and fluoride

Ferrous sulfate anhydrous

1997

Approved as Treatment by the FDA

Ferrous sulfate anhydrous, also called Tri-Vitamin with iron and fluoride, is approved by the FDA for 1 uses which include Iron Deficiency Anemia .

Iron Deficiency Anemia

Effectiveness

How Fml Affects PatientsFerrous sulfate is a supplement that replaces the iron usually found in hemoglobin and myoglobin. Iron is important for transporting oxygen, providing energy, and protecting our cells from damage. It also helps with tissue growth and keeping our DNA healthy.

How Fml works in the bodyIron plays an important role in the body, helping form red blood cells that carry oxygen around. When the body cannot produce enough normal red blood cells due to a lack of iron, it is known as iron deficiency anemia. Symptoms of iron deficiency anemia include fatigue, breathlessness, palpitations, dizziness, and headache. Taking iron supplements can help restore the body's iron levels. Iron is transported by a protein called DMT1 into macrophages, where it is stored or transported out of the macrophage. It is then oxidized and taken up by transferrin for transport in the serum to sites like the bone

When to interrupt dosage

The recommended dosage of Fml is contingent upon the diagnosed disorder, including hypochromic anemia, Lactation and Iron deficiency anemia. The measure of dosage also varies as per the technique of delivery (e.g. Tablet - Oral or Tablet, extended release - Oral) specified in the table below.

Condition

Dosage

Administration

Iron replacement therapy

, 0.05 mg/mg, 300.0 mg, 5.0 mg, 18.0 mg, 27.0 mg, 65.0 mg, 4.0 mg, 105.0 mg, 0.56 mg, 125.0 mg/mL, 60.0 mg, 15.0 mg/mL, 30.0 mg, 35.0 mg, 50.0 mg, 9.5 mg, 10.0 mg/mL, 3.6 mg/mL, 525.0 mg, 324.0 mg, 220.0 mg/mL, 325.0 mg, 0.00063 mg/mg, 11.0 mg/mL, 9.5 mg/mL

Tablet - Oral, Tablet, extended release - Oral, , Tablet, effervescent - Oral, Oral, Capsule - Oral, Tablet, extended release, Tablet, Tablet, effervescent, Tablet, coated - Oral, Topical, Solution / drops, Solution, Liquid, Tablet, film coated, Solution - Oral, Liquid - Oral, Lotion, Powder, Powder - Oral, Elixir - Oral, Solution / drops - Oral, Liquid; Tablet - Oral, Tablet, coated, Tablet, delayed release, Capsule, Tablet, film coated - Oral, Tablet, delayed release - Oral, Lotion - Topical, Capsule, extended release - Oral, Elixir, Capsule, extended release, Liquid; Tablet

Folic Acid Deficiency

Latent Iron Deficiency

breastfeeding women

hypochromic anemia

Iron Deficiency Anemia

Iron deficiency

Breastfeeding

Pregnancy

Folate deficiency

Iron Deficiency Anemia

Warnings

Fml Contraindications

Condition

Risk Level

Notes

Non-iron deficiency anemia

Do Not Combine

Hemosiderosis

Do Not Combine

Hemochromatosis

Do Not Combine

There are 20 known major drug interactions with Fml.

Common Fml Drug Interactions

Drug Name

Risk Level

Description

Raltegravir

Major

The serum concentration of Raltegravir can be decreased when it is combined with Ferrous sulfate anhydrous.

Technetium Tc-99m oxidronate

Major

Ferrous sulfate anhydrous can cause a decrease in the absorption of Technetium Tc-99m oxidronate resulting in a reduced serum concentration and potentially a decrease in efficacy.

3-Aza-2,3-Dihydrogeranyl Diphosphate

Minor

Ferrous sulfate anhydrous can cause a decrease in the absorption of 3-Aza-2,3-Dihydrogeranyl Diphosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.

Calcium phosphate dihydrate

Minor

Ferrous sulfate anhydrous can cause a decrease in the absorption of Calcium phosphate dihydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.

Ferric pyrophosphate

Minor

Ferrous sulfate anhydrous can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.

Fml Toxicity & Overdose RiskThe amount of iron in ferrous sulfate that is considered safe for humans is up to 20mg/kg, while an amount between 20-60mg/kg can lead to mild toxicity. Anything higher than 60mg/kg can cause severe symptoms. People who have overdosed on ferrous sulfate may experience nausea, gas, abdominal pain, diarrhea, constipation, dark stools, bluish lips, fingertips, and palms, drowsiness, fast heartbeat, seizures, acidosis, liver injury, and heart problems. If the patient is unresponsive or having seizures, doctors may perform gastric lavage with sodium bic